Drug Profile

AUS 001

Alternative Names: AUS-001; AUS_001

Latest Information Update: 08 Jul 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Australis Pharmaceuticals
Class Antineoplastics
Mechanism of Action Tubulin polymerisation inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Cancer

Most Recent Events

24 Jun 2024 Australis Pharmaceuticals has patent protection for AUS 001 (Australis Pharmaceuticals pipeline, June 2024)
24 Jun 2024 Australis Pharmaceuticals plans clinical trials for Pancreatic cancer, Glioblastoma and Brain metastases (Australis Pharmaceuticals pipeline, June 2024)
31 May 2024 Pharmacodynamics data from a preclinical trial in Glioblastoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com